Randomized comparison of linezolid (PNU-100766) versus oxacillin-dicloxacillin for treatment of complicated skin and soft tissue infections

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 12, 2000, Pages 3408-3413

  Stevens, D L ^a   Smith, L G ^a   Bruss, J B ^a   McConnell Martin, M A ^a   Duvall, S E ^a   Todd, W M ^a   Hafkin, B ^a  

^a Boise VA Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOXACILLIN; LINEZOLID; OXACILLIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GRAM POSITIVE BACTERIUM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SOFT TISSUE INFECTION; TREATMENT OUTCOME;

ACETAMIDES; ANTI-INFECTIVE AGENTS; DICLOXACILLIN; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OXACILLIN; OXAZOLIDINONES; PENICILLINS; SKIN DISEASES, BACTERIAL; SOFT TISSUE INFECTIONS; TREATMENT OUTCOME;

EID: 0034425844     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.12.3408-3413.2000     Document Type: Article

References (31)

1. Current concepts: Streptococcal infections of skin and soft tissues
2. Oxazolidinone antibacterial agents
3. Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
4. Update: Staphylococcus aureus with reduced susceptibility to vancomycin - United States, 1997
5. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface
6. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound
7. Interactions of monoamine oxidase with substrates and inhibitors
8. The pharmacologic and bacteriologic properties of oxazolidinones, a new class of synthetic antimicrobials
9. In vitro activities of new oxazolidinone antimicrobial agents against enterococci
10. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections
11. The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan
12. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogenously resistant to vancomycin
13. Frequency of occurrence and antimicrobial susceptibility of bacterial pathogens associated with skin and soft tissue infections during 1997 from an international surveillance programme
14. In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766, two novel fluorinated oxazolidinones
15. Soft tissue infections
16. Comparing hospital length of stay (LOS) between linezolid and vancomycin in the treatment of methicillin-resistant Staphylococci species (MRSS) infections: A randomized, multi-center clinical trial
17. In vitro activities of investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
18. Optimal treatment of complicated skin and skin structure infections
19. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
20. Methicillin-resistant Staphylococcus aureus in U.S. hospitals, 1975-1991
21. First clinical isolate of vancomycin-intermediate Staphylococcus aureus in a French hospital
22. Linezolid (PNU-10076) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: A randomized, double-blind, multicenter study
23. Comparative in vitro activity and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium
24. Antibiotic effects on bacterial viability, toxin production, and host response
25. Effect of antibiotics on toxin production and viability of Clostridium perfringens
26. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria
27. Cellulitis and superficial infections
28. Subcutaneous tissue infections and abscesses
29. Methicillin-resistant Staphylococcus aureus in Europe
30. Bacteremia caused by staphylococci with inducible vancomycin heteroresistance
31. In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents